222 related articles for article (PubMed ID: 25502488)
1. Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia.
Mizuki Y; Takaki M
J Clin Psychopharmacol; 2015 Feb; 35(1):101-2. PubMed ID: 25502488
[No Abstract] [Full Text] [Related]
2. Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.
Takaki M; Mizuki Y; Miki T
J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E14. PubMed ID: 24763772
[No Abstract] [Full Text] [Related]
3. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of QTc interval and antipsychotics.
Taylor DM
Am J Psychiatry; 2002 Jun; 159(6):1062; author reply 1064. PubMed ID: 12042205
[No Abstract] [Full Text] [Related]
5. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
6. QTc prolongation: possible association with risperidone and/or haloperidol.
Nandagopal JJ; Craig JM; Lippmann S
Psychosomatics; 2003; 44(6):521. PubMed ID: 14597690
[No Abstract] [Full Text] [Related]
7. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.
Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Saito M; Inoue Y; Someya T
Hum Psychopharmacol; 2012 Jan; 27(1):39-42. PubMed ID: 22144033
[TBL] [Abstract][Full Text] [Related]
8. Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study.
Vieweg WV; Hasnain M
Am J Psychiatry; 2011 Jun; 168(6):650-1; author reply 651. PubMed ID: 21642483
[No Abstract] [Full Text] [Related]
9. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Takahashi S; Suzuki M; Uchiyama M
Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole-associated QTc prolongation in a geriatric patient.
Hategan A; Bourgeois JA
J Clin Psychopharmacol; 2014 Dec; 34(6):766-8. PubMed ID: 25203469
[No Abstract] [Full Text] [Related]
11. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.
Ozeki Y; Fujii K; Kurimoto N; Yamada N; Okawa M; Aoki T; Takahashi J; Ishida N; Horie M; Kunugi H
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):401-5. PubMed ID: 20079791
[TBL] [Abstract][Full Text] [Related]
12. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kishi T; Matsuda Y; Iwata N
PLoS One; 2014; 9(2):e88049. PubMed ID: 24505373
[TBL] [Abstract][Full Text] [Related]
13. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
14. [Risperidone use in child and adolescent psychiatric patients].
Chevreuil C; Reymann JM; Frémaux T; Polard E; Séveno T; Bentué-Ferrer D
Therapie; 2008; 63(5):359-75. PubMed ID: 19154706
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
16. Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Yu W; Lei L; Yu Y; Li Y; Shen Y; Li H
Hum Psychopharmacol; 2020 Jan; 35(1):e2717. PubMed ID: 31837240
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
18. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
19. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
20. The position of blonanserin as a treatment for schizophrenia.
Kishi T; Matsuda Y; Iwata N
Asia Pac Psychiatry; 2014 Dec; 6(4):462. PubMed ID: 25425069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
